A US court has ruled on how five claims in two patents related to acne drug Absorica (isotretinoin) should be construed, in a patent infringement case between Canada-based Cipher Pharmaceuticals and Actavis.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Markman hearing, Cipher, Actavis, Absorica, claim construction